Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Capital Expenditures (2019 - 2025)

Historic Capital Expenditures for Avidity Biosciences (RNA) over the last 7 years, with Q3 2025 value amounting to $712000.0.

  • Avidity Biosciences' Capital Expenditures fell 5821.6% to $712000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $11.7 million, marking a year-over-year increase of 19215.05%. This contributed to the annual value of $7.1 million for FY2024, which is 6712.39% up from last year.
  • Per Avidity Biosciences' latest filing, its Capital Expenditures stood at $712000.0 for Q3 2025, which was down 5821.6% from $3.3 million recorded in Q2 2025.
  • Avidity Biosciences' 5-year Capital Expenditures high stood at $3.9 million for Q4 2024, and its period low was -$107000.0 during Q3 2022.
  • In the last 5 years, Avidity Biosciences' Capital Expenditures had a median value of $863000.0 in 2023 and averaged $1.4 million.
  • Its Capital Expenditures has fluctuated over the past 5 years, first surged by 515000.0% in 2021, then plummeted by 11337.5% in 2022.
  • Over the past 5 years, Avidity Biosciences' Capital Expenditures (Quarter) stood at $1.7 million in 2021, then crashed by 50.21% to $850000.0 in 2022, then rose by 1.53% to $863000.0 in 2023, then surged by 353.77% to $3.9 million in 2024, then plummeted by 81.82% to $712000.0 in 2025.
  • Its Capital Expenditures was $712000.0 in Q3 2025, compared to $3.3 million in Q2 2025 and $3.8 million in Q1 2025.